{"nctId":"NCT01114880","briefTitle":"Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis","startDateStruct":{"date":"2010-01"},"conditions":["Ankylosing Spondylitis"],"count":344,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: adalimumab","Other: placebo"]},{"label":"Adalimumab","type":"EXPERIMENTAL","interventionNames":["Biological: adalimumab"]}],"interventions":[{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 through 65 years\n* Has a diagnosis of ankylosing spondylitis (AS) based on the Modified New York Criteria\n* Has active AS, as defined by fulfillment of at least 2 of the following 3 conditions at both Screening and Baseline visits:\n\n  * BASDAI score at least 4 cm\n  * Total back pain on a visual analog scale (VAS) at least 40 mm\n  * Morning stiffness at least 1 hr\n* Has inadequate response to or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs) as defined by the Investigator\n\nExclusion Criteria:\n\n* Has total spinal ankylosis (bamboo spine)\n* Has undergone spinal surgery or joint surgery involving joints assessed within 2 months prior to Baseline\n* Has extra-articular manifestations (i.e., psoriasis, uveitis, inflammatory bowel disease) that is not clinically stable, as defined by the Investigator's best clinical judgment, for at least 28 days prior to Baseline\n* Has received intra-articular joint injection(s), spinal or paraspinal injection(s) with corticosteroids within 28 days prior to Baseline\n* Has prior exposure to any biologic therapy with potential therapeutic impact on AS, including anti-TNF (tumor necrosis factor) therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria","description":"ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \\[least\\] to 100 \\[worst\\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \\[BASDAI\\] scores).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting the ASAS20 Response Criteria","description":"ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \\[least\\] to 100 \\[worst\\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \\[BASDAI\\] scores).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting the ASAS40 Response Criteria","description":"An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \\[least\\] to 100 \\[worst\\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting the ASAS40 Response Criteria","description":"An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \\[least\\] to 100 \\[worst\\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting the ASAS5/6 Response Criteria","description":"An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \\[BASDAI\\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \\[BASMI\\]); and acute phase reactant (high-sensitivity C-reactive protein).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting the ASAS5/6 Response Criteria","description":"An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \\[BASDAI\\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \\[BASMI\\]); and acute phase reactant (high-sensitivity C-reactive protein).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ASAS Partial Remission","description":"Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \\[BASDAI\\] scores).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ASAS Partial Remission","description":"Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \\[BASDAI\\] scores).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Global Assessment of Disease Activity","description":"Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.8","spread":"24.16"},{"groupId":"OG001","value":"-11.7","spread":"21.77"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Global Assessment of Disease Activity","description":"Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.8","spread":"24.47"},{"groupId":"OG001","value":"-35.5","spread":"25.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Back Pain Score","description":"Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.0","spread":"23.55"},{"groupId":"OG001","value":"-13.7","spread":"22.88"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Back Pain Score","description":"Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.1","spread":"23.29"},{"groupId":"OG001","value":"-37.8","spread":"24.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score","description":"Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.5","spread":"20.18"},{"groupId":"OG001","value":"-4.7","spread":"16.40"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score","description":"Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.2","spread":"21.03"},{"groupId":"OG001","value":"-20.9","spread":"21.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Inflammation Score","description":"The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: \"How would you describe the overall level of morning stiffness you have had from the time you wake up?\", with response ranging from none to very severe; and \"How long does your morning stiffness last from the time you wake up?\", with response ranging from 0 hours to 2 or more hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"2.01"},{"groupId":"OG001","value":"-1.5","spread":"2.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Inflammation Score","description":"The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: \"How would you describe the overall level of morning stiffness you have had from the time you wake up?\", with response ranging from none to very severe; and \"How long does your morning stiffness last from the time you wake up?\", with response ranging from 0 hours to 2 or more hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"2.21"},{"groupId":"OG001","value":"-3.6","spread":"2.24"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria","description":"A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from \"none\" to \"very severe\" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria","description":"A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from \"none\" to \"very severe\" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)","description":"Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.8","spread":"23.76"},{"groupId":"OG001","value":"-4.2","spread":"21.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)","description":"Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.2","spread":"24.27"},{"groupId":"OG001","value":"-20.1","spread":"30.63"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score","description":"The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"6.43"},{"groupId":"OG001","value":"4.0","spread":"6.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score","description":"The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"7.44"},{"groupId":"OG001","value":"9.2","spread":"7.25"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":229},"commonTop":["Alanine aminotransferase increased","Upper respiratory tract infection","Aspartate aminotransferase increased","White blood cell count decreased","Blood triglycerides increased"]}}}